Evidence Snapshot

NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)

CHEMBL2111387 CHIMERIC PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T00:14:02Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 9:14 AM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL2111387

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) as ChEMBL target CHEMBL2111387, mapped to UniProt Q9UM73. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)

CHIMERIC PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL2111387

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q9UM73

ALK tyrosine kinase receptor

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) matters

As of 2026-09-14

NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) is reviewed as ALK tyrosine kinase receptor (UniProt Q9UM73); NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 90 compounds, and 46 assays, with lead potency reaching pChEMBL 8.7.

Protein context

ALK tyrosine kinase receptor

ALK tyrosine kinase receptor Sequence length is 1620 aa.

Review this target as NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor), mapped to UniProt Q9UM73. ChEMBL maps the protein component as ALK tyrosine kinase receptor. Sequence length is 1620 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9UM73 Protein

Disease context

cancer

NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CERITINIB, CRIZOTINIB.

Start review with cancer because it currently carries approved-linked support. Linked drugs include CERITINIB, CRIZOTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 2 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 90 compounds, and 46 assays for this target. The dominant activity type is IC50. CHEMBL601719 is the current potency anchor at pChEMBL 8.7.

Use CHEMBL601719 as the tractability anchor when discussing potency (pChEMBL 8.7).

Activity source · ChEMBL 36 via Core Engine

3 approved pChEMBL 8.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UM73, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

Total Compounds

Total Assays

Approved Drugs

IC50: 102.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL601719	8.7	IC50	Approved
No preferred name CHEMBL4762256	8.5	IC50	—
No preferred name CHEMBL3545360	8.2	IC50	—
No preferred name CHEMBL4762861	8.2	IC50	—
No preferred name CHEMBL4798141	7.9	IC50	—